GI Dynamics Announces Commercial Availability of the EndoBarrier® for the Treatment of Type 2 Diabetes and/or Obesity in the Netherlands

1/4/2012 7:23:43 AM

LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) today announced the transition of the EndoBarrier® Gastrointestinal Liner (the EndoBarrier), a novel, non-surgical device for the treatment of type 2 diabetes and/or obesity, from clinical research to commercial use in the Netherlands. To date, nearly 100 patients have been treated with the EndoBarrier in clinical trials conducted in the Netherlands.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• GI Dynamics

• Medical Devices

• Medical Dev. & Diag. - Product News

• Medical Dev. & Diag. - Industry